MRKR · Marker Therapeutics Inc

-

Please sign in to comment on MRKR

1 Comment

Admin

4 years, 1 month ago

Marker Therapeutics, Inc is currently in a long term uptrend where the price is trading 27.2% above its 200 day moving average.

From a valuation standpoint, the stock is 83.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 225.7.

Marker Therapeutics, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.

Its net income has dropped by 67.5% to $-9M since the same quarter in the previous year.

Finally, its free cash flow fell by 110.0% to $-10M since the same quarter in the previous year.

Based on the above factors, Marker Therapeutics, Inc gets an overall score of 2/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US57055L1070
Sector	Healthcare
Industry	Biotechnology

Market Cap	13M
PE Ratio	None
Target Price	6
Beta	1.29
Dividend Yield	None

ABOUT

Marker Therapeutics Inc

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

MRKR · Marker Therapeutics Inc

-

Marker Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Marker Therapeutics Inc using a moving average strategy